Research advances in second-line therapies for hepatocellular carcinoma after resistance to targeted therapy combined with immunotherapy
- VernacularTitle:肝癌靶向联合免疫治疗耐药后的二线治疗方案研究进展
- Author:
Tianqi ZHANG
1
;
Yuzhe CAO
1
;
Mengxuan ZUO
1
;
Yangkui GU
1
Author Information
- Publication Type:Review
- Keywords: Carcinoma， Hepatocellular; Drug Therapy; Drug Resistance， Neoplasm
- From: Journal of Clinical Hepatology 2024;40(2):386-390
- CountryChina
- Language:Chinese
- Abstract: In recent years， clinical studies on targeted therapy and immunotherapy for advanced hepatocellular carcinoma used alone or in combination have provided abundant evidence on efficacy and safety for the selection of first-line therapies. However， no consensus has been reached on the selection of second-line therapies in various clinical guidelines for hepatocellular carcinoma， which is caused by the fact that existing evidence is limited to the options after failure of sorafenib and that there is still a lack of high-level evidence for new first-line therapies such as second-line therapies after resistance to targeted therapy and immunotherapy for hepatocellular carcinoma. This article reviews the results of current clinical trials and summarizes the studies on second-line therapies for hepatocellular carcinoma after resistance to first-line targeted therapy and immunotherapy for hepatocellular carcinoma based on the different mechanisms of action of drugs， as well as the research advances in recent years. For hepatocellular carcinoma patients with resistance to first-line targeted therapy and immunotherapy， targeted combination therapy and dual-immune therapy are expected to improve treatment outcome and survival， and more prospective clinical studies are needed in the future to provide effective and safe treatment regimens for hepatocellular carcinoma patients with resistance to targeted therapy and immunotherapy.
